Brian I. Rini, MD, FASCO, is professor of medicine and chief of clinical trials for the Vanderbilt Ingram Cancer Center (VICC) at Vanderbilt University in Nashville, Tennessee. His primary research has been in renal cell carcinoma, with special focus on antiangiogenic therapy and immunotherapy. Dr Rini’s research has been published in peer-reviewed journals, including the New England Journal of Medicine, Journal of the National Cancer Institute, Journal of Clinical Oncology, and Lancet. Certified in Medical Oncology by the American Board of Internal Medicine, he is active in numerous professional organizations, such as ASCO and the Society for Immunotherapy of Cancer (SITC). Dr Rini earned his medical degree at the Ohio State University College of Medicine in Columbus.